Imricor Medical Systems (ASX:IMR) started the VISABL-VT clinical trial after performing the first-in-human ventricular ablation guided by real-time interventional cardiac magnetic resonance (iCMR) at the Amsterdam University Medical Center, according to a Friday filing with the Australian bourse.
The trial evaluates the safety and effectiveness of radiofrequency ablation of ventricular tachycardia in ischemic cardiomyopathy using the Vision-MR Ablation Catheter 2.0 in the iCMR environment.
The patient was treated for both right-sided and left-sided premature ventricular complexes, the filing said.
Ventricular ablation is a procedure used to treat ventricular tachycardia, a rapid, abnormal heartbeat.
Price (AUD): $1.36, Change: $+0.18, Percent Change: +14.83%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。